Practicefirst would like to notify its clients of another new CPT code introduced by AMA related to the COVID-19 testing. Per AMA this code was introduced because, “There is no code that describes multiplex immunoassay antigen testing for these three viral targets, i.e. SARS-CoV, SARS-CoV-2 [COVID-19], and influenza virus types A and B. A code to report a multiplex viral pathogen panel using an antigen immunoassay technique would facilitate reporting SARS-CoV-2 testing, along with influenza types A and B in the differential diagnosis”.
This new code is effective immediately for use in reporting this laboratory test. The description of the code is as follows:
87428: Infectious agent antigen detection by immunoassay technique, (e.g. enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (e.g. SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B
For more details regarding the new CPT code, 87428 please read the CPT Assistant November special edition.
The annual revision to the CPT code set will go into effect on January 1, 2021. This will include the new E/M guidelines for the office visit codes. Practicefirst will continue to communicate with its clients regarding all the CPT changes for 2021